https://scholars.lib.ntu.edu.tw/handle/123456789/590115
Title: | Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan | Authors: | Chen, Yi-Wei Lee, Yi-Yen Lin, Chun-Fu Pan, Po-Shen Chen, Jen-Kun CHUN-WEI WANG Hsu, Shih-Ming Kuo, Yu-Cheng Lan, Tien-Li Hsu, Sanford P C Liang, Muh-Lii Chen, Robert Hsin-Hung Chang, Feng-Chi Wu, Chih-Chun Lin, Shih-Chieh Liang, Hsiang-Kuang Lee, Jia-Cheng Chen, Shih-Kuan Liu, Hong-Ming Peir, Jinn-Jer Lin, Ko-Han Huang, Wen-Sheng Chen, Kuan-Hsuan Kang, Yu-Mei Liou, Shueh-Chun Wang, Chun-Chieh Pai, Ping-Ching Li, Chih-Wei Chiek, Daniel Quah Song Wong, Tai-Tong Chiou, Shih-Hwa Chao, Yee Tanaka, Hiroki Chou, Fong-In HSIANG-KUANG LIANG et al. |
Keywords: | BNCT; T/B ratio; T/N ratio; glioblastoma; radioresistance | Issue Date: | 15-Apr-2021 | Journal Volume: | 10 | Journal Issue: | 4 | Source: | Biology | Abstract: | Although boron neutron capture therapy (BNCT) is a promising treatment option for malignant brain tumors, the optimal BNCT parameters for patients with immediately life-threatening, end-stage brain tumors remain unclear. We performed BNCT on 34 patients with life-threatening, end-stage brain tumors and analyzed the relationship between survival outcomes and BNCT parameters. Before BNCT, MRI and 18F-BPA-PET analyses were conducted to identify the tumor location/distribution and the tumor-to-normal tissue uptake ratio (T/N ratio) of 18F-BPA. No severe adverse events were observed (grade ≥ 3). The objective response rate and disease control rate were 50.0% and 85.3%, respectively. The mean overall survival (OS), cancer-specific survival (CSS), and relapse-free survival (RFS) times were 7.25, 7.80, and 4.18 months, respectively. Remarkably, the mean OS, CSS, and RFS of patients who achieved a complete response were 17.66, 22.5, and 7.50 months, respectively. Kaplan-Meier analysis identified the optimal BNCT parameters and tumor characteristics of these patients, including a T/N ratio ≥ 4, tumor volume < 20 mL, mean tumor dose ≥ 25 Gy-E, MIB-1 ≤ 40, and a lower recursive partitioning analysis (RPA) class. In conclusion, for malignant brain tumor patients who have exhausted all available treatment options and who are in an immediately life-threatening condition, BNCT may be considered as a therapeutic approach to prolong survival. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/590115 | ISSN: | 2079-7737 | DOI: | 10.3390/biology10040334 |
Appears in Collections: | 醫學院附設醫院 (臺大醫院) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.